These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23512765)

  • 1. FDA is to assess data linking type 2 diabetes drugs with pancreatitis.
    Cohen D
    BMJ; 2013 Mar; 346():f1808. PubMed ID: 23512765
    [No Abstract]   [Full Text] [Related]  

  • 2. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
    Kmietowicz Z
    BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
    [No Abstract]   [Full Text] [Related]  

  • 4. Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm.
    Cohen D
    BMJ; 2013 Jun; 346():f3900. PubMed ID: 23775889
    [No Abstract]   [Full Text] [Related]  

  • 5. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
    Parks M; Rosebraugh C
    N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
    [No Abstract]   [Full Text] [Related]  

  • 6. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of pancreatitis with glucagon-like peptide-1 agonist use.
    Anderson SL; Trujillo JM
    Ann Pharmacother; 2010 May; 44(5):904-9. PubMed ID: 20371755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
    Schectman J
    Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
    [No Abstract]   [Full Text] [Related]  

  • 9. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
    Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
    [No Abstract]   [Full Text] [Related]  

  • 12. A cohort study of acute pancreatitis in relation to exenatide use.
    Dore DD; Bloomgren GL; Wenten M; Hoffman C; Clifford CR; Quinn SG; Braun DK; Noel RA; Seeger JD
    Diabetes Obes Metab; 2011 Jun; 13(6):559-66. PubMed ID: 21320263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperplasia from GLP-1 drugs is "not a surprise," say researchers.
    Cohen D
    BMJ; 2013 Mar; 346():f2025. PubMed ID: 23535260
    [No Abstract]   [Full Text] [Related]  

  • 14. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 15. Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
    Cohen D
    BMJ; 2013 Apr; 346():f2607. PubMed ID: 23613543
    [No Abstract]   [Full Text] [Related]  

  • 16. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
    Cohen D
    BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395
    [No Abstract]   [Full Text] [Related]  

  • 17. Consumer group calls for antidiabetes drug to be withdrawn.
    Lenzer J
    BMJ; 2012 May; 344():e3259. PubMed ID: 22570213
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
    Funch D; Gydesen H; Tornøe K; Major-Pedersen A; Chan KA
    Diabetes Obes Metab; 2014 Mar; 16(3):273-5. PubMed ID: 24199745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modern medical treatment of type 2 diabetes].
    Hanefeld M; Bornstein SR; Barthel A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2494-7. PubMed ID: 25423454
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.